Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Spero Therapeutics Inc (SPRO) today and set a price target of $27. The company’s shares closed yesterday at $12.07.
Chen said:
“We rate SPRO Overweight. As the company advances its pipeline toward commercialization, we expect upward earnings revisions and multiple expansion to levels not reflected in FactSet consensus expectations to drive SPRO’s stock higher. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our $27 12-month price target. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of EV/EBITDA and DCF analysis to arrive at our $27 12-month price target.”
According to TipRanks.com, Chen is a 5-star analyst with an average return of 12.3% and a 45.6% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Amneal Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Spero Therapeutics Inc with a $27 average price target, which is a 123.7% upside from current levels. In a report issued on March 14, Oppenheimer also assigned a Buy rating to the stock with a $30 price target.
See today’s analyst top recommended stocks >>
Based on Spero Therapeutics Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $10.6 million. In comparison, last year the company had a GAAP net loss of $13.86 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206.
